AnaptysBio Inc (ANAB)vsAstraZeneca PLC (AZN)
ANAB
AnaptysBio Inc
$65.73
+5.44%
HEALTHCARE · Cap: $1.81B
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 24938% more annual revenue ($58.74B vs $234.60M). AZN leads profitability with a 17.4% profit margin vs -5.6%. AZN earns a higher WallStSmart Score of 64/100 (C+).
ANAB
Hold41
out of 100
Grade: D
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.6%
Fair Value
$411.61
Current Price
$65.73
$345.88 discount
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 61.8%
Revenue surging 151.1% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 49.4x book value
ROE of -24.5% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ANAB
The strongest argument for ANAB centers on Operating Margin, Revenue Growth, Debt/Equity. Revenue growth of 151.1% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bear Case : ANAB
The primary concerns for ANAB are EPS Growth, Market Cap, Price/Book.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
ANAB profiles as a hypergrowth stock while AZN is a value play — different risk/reward profiles.
ANAB carries more volatility with a beta of 0.41 — expect wider price swings.
ANAB is growing revenue faster at 151.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 41/100), backed by strong 17.4% margins. ANAB offers better value entry with a 86.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AnaptysBio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?